Drugs

Papers
(The TQCC of Drugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Acknowledgement to Referees503
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”322
Targeting DNA Damage Response Deficiency in Thoracic Cancers285
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema270
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression232
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments206
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences177
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using174
Eftrenonacog Alfa: A Review in Haemophilia B171
Spesolimab for the Treatment of Generalized Pustular Psoriasis158
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations154
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms149
Senaparib: First Approval142
New Therapies on the Horizon for Primary Biliary Cholangitis135
Vorasidenib: First Approval131
Aprocitentan: First Approval114
Teclistamab: First Approval111
Epcoritamab: First Approval108
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,107
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments99
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial99
Drugs in Development to Manage Acute Pain97
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure96
Tolebrutinib: First Approval95
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses92
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms92
Danicopan: First Approval91
Repotrectinib: First Approval86
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies86
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer84
Acoltremon: First Approval83
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?82
Cosibelimab: First Approval81
Androgenetic Alopecia: Therapy Update79
Lenacapavir: First Approval79
Ivarmacitinib Sulfate: First Approval78
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine74
Cancer Pain Treatment Strategies in Patients with Cancer72
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids72
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?70
Sibeprenlimab: First Approval69
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?69
Mazdutide: First Approval68
Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians66
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification65
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema65
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection63
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough62
Pozelimab: First Approval61
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes60
Correction to: Tapinarof Cream 1%: First Approval60
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?59
Taletrectinib: First Approval57
Ifupinostat: First Approval55
Correction to: Prevention and Treatment of Monkeypox53
The Place of Cannabinoids in the Treatment of Gynecological Pain52
Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews51
Sunvozertinib: First Approval51
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology50
Managing Burning Mouth Syndrome: Current and Future Directions50
Comparative Efficacy of Non-opioid Analgesic Drugs for Chronic Cancer Pain: A Bayesian Network Meta-analysis50
Pixavir Marboxil: First Approval50
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned49
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options48
Targeting Inflammation in Bronchiectasis48
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis47
Tovorafenib: First Approval47
Correction to: Concizumab: First Approval46
Dorzagliatin: First Approval46
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades45
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies44
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology44
Correction to: Remdesivir: A Review in COVID-1944
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials43
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study43
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond43
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab43
Advances in Immune-Based Approaches for the Cure of HIV Infection43
Ozoralizumab: First Approval42
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib42
Birch Bark Extract: A Review in Epidermolysis Bullosa42
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review42
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses42
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’41
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?41
Givinostat: First Approval40
Catumaxomab: First Approval39
Gepirone Extended-Release: First Approval39
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies38
Tirzepatide: A Review in Type 2 Diabetes38
Fezolinetant: First Approval38
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency37
Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects37
Correction: Ifupinostat: First Approval37
Becotatug Vedotin: First Approval37
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale36
Ensitrelvir Fumaric Acid: First Approval36
Futibatinib: First Approval36
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy36
Relacorilant: First Approval35
Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis35
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study34
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes34
Correction: Teprotumumab: A Review in Thyroid Eye Disease34
Correction: Iptacopan: First Approval34
Avacincaptad Pegol: First Approval34
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults34
Atrasentan: First Approval34
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials33
Beremagene Geperpavec: First Approval33
Zeprumetostat: First Approval33
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?33
Managing Pain in Fibromyalgia: Current and Future Options33
Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review32
Eye Involvement and Management in Inherited Epidermolysis Bullosa32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease32
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 131
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease31
Lotilaner Ophthalmic Solution 0.25%: First Approval31
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases31
Zastaprazan: First Approval31
Imetelstat: First Approval31
Acknowledgement to Referees30
Nogapendekin alfa Inbakicept: First Approval30
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry30
Etripamil: First Approval29
Sepiapterin: First Approval29
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management29
Crinecerfont: First Approval29
EGFR Exon 20 Insertion–Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions29
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid29
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials28
Retifanlimab: First Approval28
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews28
Diagnosis and Treatment of AL Amyloidosis28
Rovadicitinib: First Approval28
Revumenib: First Approval28
Mavorixafor: First Approval27
Tradipitant: First Approval27
Correction to: Sparsentan: First Approval27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”27
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study27
Correction: Zastaprazan: First Approval27
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes27
Correction to: Spesolimab: First Approval27
Methadone for Cancer Pain Management in Children: A Review of Literature27
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial26
Ravulizumab: A Review in Generalised Myasthenia Gravis26
Keverprazan Hydrochloride: First Approval25
Remdesivir: A Review in COVID-1925
Onradivir: First Approval25
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy25
Zolbetuximab: First Approval25
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval25
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer25
0.078198909759521